These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36752579)

  • 21. Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma.
    Roccuzzo G; Fava P; Astrua C; Brizio MG; Cavaliere G; Bongiovanni E; Santaniello U; Carpentieri G; Cangiolosi L; Brondino C; Pala V; Ribero S; Quaglino P
    Cancers (Basel); 2024 Sep; 16(17):. PubMed ID: 39272953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.
    Rigo R; Ding PQ; Batuyong E; Cheung WY; Walker J; Monzon JG; Cheng T
    Oncologist; 2024 Jan; 29(1):57-66. PubMed ID: 37648247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
    Bhave P; Hong A; Lo SN; Johnson R; Mangana J; Johnson DB; Dulgar O; Eroglu Z; Yeoh HL; Haydon A; Lodde GC; Livingstone E; Khattak A; Kähler K; Hausschild A; McArthur GA; Menzies AM; Long G; Wang W; Carlino MS
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 25. Adjuvant treatment for melanoma in clinical practice - Trial versus reality.
    de Meza MM; Ismail RK; Rauwerdink D; van Not OJ; van Breeschoten J; Blokx WAM; de Boer A; van Dartel M; Hilarius DL; Ellebaek E; Bonenkamp HJ; Blank CU; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JWB; Haanen JB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil A; Westgeest HM; van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
    Eur J Cancer; 2021 Nov; 158():234-245. PubMed ID: 34600790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.
    Mo Z; Liu J; Zhang J; Deng Y; Xu M; Jiang Y
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110973. PubMed ID: 37769536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
    Ascierto PA; Di Giacomo AM; Chiarion Sileni V; Queirolo P; Spagnolo F; De Galitiis F; Cognetti F; Mandalà M; Guidoboni M; Rinaldi G; Depenni R; Consoli F; Troiani T; Guida M; Marconcini R; Ferrucci PF; Strippoli S; Fava P; Merelli B; Simeone E; Di Guardo L; Giannarelli D; Maio M; Quaglino P; Del Vecchio M
    Eur J Cancer; 2023 Sep; 191():113246. PubMed ID: 37549531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel adjuvant options for cutaneous melanoma.
    Dimitriou F; Long GV; Menzies AM
    Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
    Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
    Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
    Eckardt J; Schroeder C; Martus P; Armeanu-Ebinger S; Kelemen O; Gschwind A; Bonzheim I; Eigentler T; Amaral T; Ossowski S; Rieß O; Flatz L; Garbe C; Forschner A
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):833-840. PubMed ID: 35192052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of adjuvant immune checkpoint inhibitor therapy in melanoma: a retrospective study.
    Sarah F; Margot R; Valerie B; Alexander D; Lieve B; Sylvie R; Celine J; Michael S
    Acta Clin Belg; 2024 Sep; ():1-9. PubMed ID: 39268967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
    Owen CN; Shoushtari AN; Chauhan D; Palmieri DJ; Lee B; Rohaan MW; Mangana J; Atkinson V; Zaman F; Young A; Hoeller C; Hersey P; Dummer R; Khattak MA; Millward M; Patel SP; Haydon A; Johnson DB; Lo S; Blank CU; Sandhu S; Carlino MS; Larkin JMG; Menzies AM; Long GV
    Ann Oncol; 2020 Aug; 31(8):1075-1082. PubMed ID: 32387454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL.
    Rogiers A; Willemot L; McDonald L; Van Campenhout H; Berchem G; Jacobs C; Blockx N; Rorive A; Neyns B
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland.
    Staeger R; Martínez-Gómez JM; Turko P; Ramelyte E; Kraehenbuehl L; Del Prete V; Hasan Ali O; Levesque MP; Dummer R; Nägeli MC; Mangana J
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or
    Placzke J; Rosińska M; Sobczuk P; Ziętek M; Kempa-Kamińska N; Cybulska-Stopa B; Kamińska-Winciorek G; Bal W; Mackiewicz J; Galus Ł; Las-Jankowska M; Jankowski M; Dziura R; Drucis K; Borkowska A; Świtaj T; Rogala P; Kozak K; Klimczak A; Jagodzińska-Mucha P; Szumera-Ciećkiewicz A; Koseła-Paterczyk H; Rutkowski P
    Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
    Stahlie EHA; Zijlker LP; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
    Melanoma Res; 2024 Feb; 34(1):63-69. PubMed ID: 38016153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.